Punjab-based Jackson Laboratories is contesting the state government's decision to revoke its manufacturing licenses. The regulator took action following reports of spurious Oxytocin injections linked to fatalities in Rajasthan. The company denies the allegations, arguing that its products were not responsible for the reported adverse events and questioning the testing procedures used by officials.
Detailed Coverage
Jackson Laboratories, a pharmaceutical manufacturer located in Punjab, has formally challenged the state government’s decision to cancel its drug manufacturing licenses. This regulatory action follows an investigation into reports of substandard or spurious batches of Oxytocin—a hormone injection used to induce labor and prevent heavy bleeding during childbirth—which gained attention after medical complications were reported at a hospital in Kota, Rajasthan.
In a recent response to the Punjab health department, the company has explicitly denied the allegations of poor product quality. Jackson Laboratories contends that the testing methodology and the findings cited by the state’s assistant commissioner of drugs are flawed. A key part of the company’s defense rests on statements purportedly issued by the Kota medical facility, which the firm claims have indicated that the negative patient outcomes were not linked to their specific product.
The company further argued that it is being unfairly held responsible for incidents occurring in various other locations across Rajasthan, including Bikaner, Jodhpur, and Banswara. Jackson Laboratories maintains that its products were not supplied to or used in several of these areas where other fatalities were reported, suggesting that the regulatory action taken against its license may be based on incorrect assumptions regarding product distribution and causality.
Regulatory authorities had initially moved to cancel the company’s licenses in June after reports emerged that certain vials labeled as Oxytocin contained only water, lacking the necessary active pharmaceutical ingredients. Such incidents often trigger intense scrutiny from drug regulators because they directly impact patient safety and the integrity of the medical supply chain.
The firm is currently seeking to present its arguments before the Punjab health secretary to contest the cancellation order. While a hearing was initially expected, it has been adjourned, and a new date for the proceedings is yet to be finalized. For investors and stakeholders, the core monitorable remains the company’s ability to resolve these regulatory hurdles. The outcome of the upcoming meetings with health authorities will be critical in determining whether the company can resume manufacturing or if it will face further long-term operational restrictions.